Trial Profile
A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary)
- Indications Cancer
- Focus Adverse reactions; Registrational
- Sponsors Merck Sharp & Dohme Corp.
- 24 Jun 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
- 24 Jun 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
- 24 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.